COVID ARDS interim analysis, page-9

Please do some research. We've been talking about this on here since May.

We haven't given up on mortality. But as others have replied, also consider the secondary outcomes, including days on mechanical ventilation, apparently the key determinant for Rem-vir approval.

We understand that our trial is taking place in the best teaching and research hospitals in the US. Obviously this will be reflected in the standard of care and mortality for the placebo group.

But we also have confidence in the process and decision making of the DSMB. Particularly in the overall context of the pandemic and its effect on the US.

For example, if you are admitted to an ICU in a smaller US hospital then you have a more than three (3) times higher rate of mortality. The implication for the 50,000+ daily new cases and 1000+ daily deaths geographically right across the US is obvious.



https://www.wbur.org/commonhealth/2020/07/15/covid-hospital-mortality-death-bigger

We believe Mesoblast and Rem-L will a be part of the answer.

GLTAH!